This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fraher, L. J. Articles by Hodsman, A. B. Search for Related Content PubMed PubMed Citation Articles by Fraher, L. J. Articles by Hodsman, A. B.

Comparison of the Biochemical Responses to Human Parathyroid Hormone-(1–31)NH₂ and hPTH-(1–34) in Healthy Humans¹

Departments of Medicine (L.J.F., R.A., P.H.W., A.B.H.) and Biochemistry (L.J.F.), The Lawson Research Institute, St. Joseph’s Health Center, University of Western Ontario, London, Ontario, Canada N6A 4V2; the Departments of Medicine and Physiology (G.N.H., J.E.H., K.L.C., D.G.), McGill University, Montreal, Quebec, Canada; and the Institute for Biological Sciences, National Research Council (P.M., G.E.W., J.F.W.), Ottawa, Ontario, Canada

Address all correspondence and requests for reprints to: Dr. Laurence J. Fraher, Room G-442, St. Joseph’s Health Center, 268 Grosvenor Street, London, Ontario, Canada N6A 4V2. E-mail: lfraher{at}lri.stjosephs.london.on.ca

The 1–31 fragment of human PTH [hPTH-(1–31)NH₂] has been shown, like hPTH-(1–34), to have anabolic effects on the skeletons of ovariectomized rats when given intermittently, but, unlike hPTH-(1–34), it does so without affecting serum calcium concentrations and does not activate the protein kinase C second messenger pathway in some target cells. To investigate the biochemical responses to hPTH-(1–31) in humans, we have directly compared it to hPTH-(1–34) during the course of slow infusions of each. Ten healthy adults, five men and five women, aged 26 ± 5 yr (range, 22–37), each received 8-h continuous infusions of 8 pmol/kg·h hPTH-(1–34) and hPTH-(1–31) given in random order at least 2 weeks apart. During the infusions there were significant increases in both plasma and urinary cAMP (P < 0.05), but there were no differences in the responses between the two peptides (P = 0.362 for plasma; P = 0.987 for urine). There were also significant phosphaturic and natriuretic responses to the two peptides, which again were not different between peptides. During the infusion of hPTH-(1–34) serum ionized calcium (Ca²⁺) increased from 1.21 ± 0.033 to 1.29 ± 0.046 mmol/L (P < 0.01), and endogenous hPTH-(1–84) decreased from 29.6 ± 9 to 15.0 ± 5.7 pg/mL (P < 0.01), such that there was a negative correlation between them (r² = 0.45). However, when hPTH-(1–31) was infused, neither serum Ca²⁺ (1.24 ± 0.03 vs. 1.25 ± 0.03) nor hPTH-(1–84) (26.8 ± 5 vs. 30.7 ± 12 pg/mL) was affected. Circulating concentrations of 1,25-dihydroxyvitamin D₃ increased from 92 ± 42 to 131 ± 63 pmol/L (P < 0.05) during infusion of hPTH-(1–34) and from 92 ± 27 to 110 ± 42 pmol/L (P = NS) during hPTH-(1–31) infusion. There was also a significant increase in the urinary measure of type I collagen degradation of amino-terminal telopeptides from 78 ± 45 to 101 ± 51 nmol/mmol creatinine (P < 0.05) when hPTH-(1–34) was infused, but it was not affected (68 ± 30 vs. 66 ± 24 nmol/mmol creatinine) by hPTH-(1–31). Therefore, hPTH-(1–31) appears to be equivalent and equipotent to hPTH-(1–34) in the release of cAMP from target tissues and the renal handling of phosphate and sodium. However, at the doses employed, it does not increase serum calcium, is a weaker stimulator of the 25-hydroxyvitamin D-1-hydroxylase, and does not induce rapid bone resorption.

This article has been cited by other articles:

				L. Gehrig, J. Lane, and M. I. O'Connor Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1362 - 1374. [Full Text] [PDF]

				C. Galli, L. A. Zella, J. A. Fretz, Q. Fu, J. W. Pike, R. S. Weinstein, S. C. Manolagas, and C. A. O'Brien Targeted Deletion of a Distant Transcriptional Enhancer of the Receptor Activator of Nuclear Factor-{kappa}B Ligand Gene Reduces Bone Remodeling and Increases Bone Mass Endocrinology, January 1, 2008; 149(1): 146 - 153. [Abstract] [Full Text] [PDF]

				X. Li, H. Liu, L. Qin, J. Tamasi, M. Bergenstock, S. Shapses, J. H. M. Feyen, D. A. Notterman, and N. C. Partridge Determination of Dual Effects of Parathyroid Hormone on Skeletal Gene Expression in Vivo by Microarray and Network Analysis J. Biol. Chem., November 9, 2007; 282(45): 33086 - 33097. [Abstract] [Full Text] [PDF]

				E. Canalis, A. Giustina, and J. P. Bilezikian Mechanisms of Anabolic Therapies for Osteoporosis N. Engl. J. Med., August 30, 2007; 357(9): 905 - 916. [Full Text] [PDF]

				C. A. O'Brien, R. L. Jilka, Q. Fu, S. Stewart, R. S. Weinstein, and S. C. Manolagas IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E784 - E793. [Abstract] [Full Text] [PDF]